Drugs Used in Rheumatoid Arthritis

On this page

RA & DMARDs Intro - Joint Warfare Kickoff

  • Rheumatoid Arthritis (RA): Chronic, autoimmune, systemic inflammatory disease targeting synovial joints.
  • Pathogenesis: Immune attack (T/B cells, Mφ) + cytokines (TNF-α, IL-1, IL-6) → synovitis, pannus, joint destruction.
  • Goals: Remission/low activity, ↓inflammation/pain, prevent damage, ↑QoL.
  • DMARDs (Disease-Modifying Antirheumatic Drugs):
    • csDMARDs (Conventional Synthetic)
    • tsDMARDs (Targeted Synthetic)
    • bDMARDs (Biologic)

⭐ Early aggressive treatment with DMARDs is crucial to prevent irreversible joint damage and disability in RA.

csDMARDs - Classic Joint Defenders

⭐ Methotrexate is the anchor csDMARD for RA; co-administration of folic acid (e.g., 5 mg/week) is essential to mitigate its hematologic, GI, and hepatic side effects.

DrugMoAKey ADRs (📌 MTX: Myelosuppression, Stomatitis, Liver fibrosis, Pneumonitis)ContraindicationsMonitoring
Methotrexate (MTX)DHFR inhibitorMyelosuppression, Stomatitis, Liver fibrosis, PneumonitisPregnancy, liver/renal diseaseCBC, LFTs, Scr
Sulfasalazine (SSZ)Anti-inflam., immunomod.GI upset, rash, oligospermia, yellow-orange urineSulfa allergy, G6PD def.CBC, LFTs
Leflunomide (LEF)DHODH inhibitorDiarrhea, hepatotoxicity, alopecia, HTNPregnancy, liver diseaseCBC, LFTs, BP
Hydroxychloroquine (HCQ)TLR inhib., ↑lysosomal pHRetinopathy, GI upset, rashPre-existing maculopathyEye exam (baseline, annual >5yrs)

bDMARDs (TNF & IL-6) - Cytokine Storm Tamers

Biological DMARDs (bDMARDs) targeting Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-6 (IL-6) are pivotal in Rheumatoid Arthritis (RA) management by downregulating inflammatory cytokine pathways.

FeatureTNF-α InhibitorsIL-6R Antagonists
ExamplesEtanercept, Infliximab, Adalimumab, Golimumab, CertolizumabTocilizumab, Sarilumab
MechanismNeutralize TNF-α, reducing inflammation.Block IL-6 receptor, inhibiting IL-6 signaling.
Key ADRs↑ Infections (esp. TB reactivation), demyelination, injection site reactions.↑ Infections, dyslipidemia, ↑ LFTs, GI perforation (rare).
Pre-screeningLatent TB, Hepatitis B/C.Latent TB, Hepatitis B/C, LFTs, lipid profile.

More Biologics & JAKinibs - Precision Joint Ops

  • Other bDMARDs:
    • Abatacept: T-cell co-stimulation modulator. For moderate-severe RA.
    • Rituximab: Anti-CD20 B-cell depleter. For TNF-inhibitor refractory RA. ADR: ⚠️ PML.
  • JAK Inhibitors (tsDMARDs - Oral):
    • Tofacitinib, Baricitinib, Upadacitinib.
    • MOA: Inhibit Janus Kinase (JAK) enzymes.
    • ADRs: Infections (herpes zoster), cytopenias, ↑ lipids.

    ⭐ JAK inhibitors (e.g., Tofacitinib) are oral targeted DMARDs but carry FDA boxed warnings for increased risk of serious infections, malignancy, major adverse cardiovascular events (MACE), and thrombosis. oka

Adjuncts & Strategy - Relief Crew & Tactics

  • NSAIDs: Symptomatic relief (pain, inflammation). No disease modification. Key ADRs: GI, renal.
  • Glucocorticoids: Rapid symptom control (bridging/flares). Bridging: <10mg/day prednisone. ADRs: osteoporosis. Taper ASAP.

    ⭐ Glucocorticoids are used for rapid symptom control in RA (bridging therapy or flare management) but should be tapered to the lowest effective dose or discontinued as soon as possible due to long-term side effects.

  • Strategy:
    • Treat-to-Target (T2T): Aim remission/Low Disease Activity (LDA).
    • Combination DMARDs.
    • Monitor disease activity (DAS28).

High‑Yield Points - ⚡ Biggest Takeaways

  • Methotrexate (MTX) is the anchor DMARD for RA, typically first-line.
  • Leflunomide inhibits dihydroorotate dehydrogenase; an alternative to MTX.
  • Sulfasalazine is used for mild RA and IBD; may cause oligospermia.
  • Hydroxychloroquine (HCQ) is safest DMARD in pregnancy; requires retinal screening.
  • TNF-α inhibitors (e.g., Infliximab, Adalimumab) increase risk of TB reactivation.
  • Rituximab, a CD20 inhibitor, depletes B-cells.
  • Tofacitinib is an oral JAK inhibitor, a newer targeted DMARD.

Unlock the full lesson and continue reading

Signup to continue reading this lesson and unlimited access questions, flashcards, AI notes, and more

Scan to download app

Scan to download
UNLOCK FREE ACCESS

Practice Questions: Drugs Used in Rheumatoid Arthritis

  1. 1. Which of the following substances is NOT classified as an opioid?

    • A. Methadone
    • B. Ketamine
    • C. Heroin
    • D. Fentanyl
    Show answer

    Answer: B. Ketamine

    Ketamine - Ketamine is a dissociative anesthetic, not an opioid, and does not primarily act through opioid receptors. - Its principal mechanism is NMDA receptor antagonism, making it the correct choice for the substance not classified as an opioid. Methadone - Methadone is a synthetic opioid used for opioid-dependence treatment and chronic pain management. - Its primary action is mu-opioid receptor agonism, with a relatively long duration of action; therefore, it is not the exception. Heroin - Heroin is a semisynthetic opioid derived from morphine and rapidly crosses the blood–brain barrier. - It is metabolized to morphine, which produces potent analgesia through mu-opioid receptor agonism; therefore, it is classified as an opioid. Fentanyl - Fentanyl is a highly potent synthetic opioid analgesic, substantially more potent than morphine. - It produces strong analgesic and sedative effects through mu-opioid receptor activation, so it is not the non-opioid option.

  2. 2. A 40-year-old woman with biliary colic develops worsening pain immediately after an analgesic injection in hospital. Which drug was most likely administered?

    • A. Morphine
    • B. Ketorolac
    • C. Nefopam
    • D. Diclofenac
    Show answer

    Answer: A. Morphine

    Morphine - Morphine stimulates mu-opioid receptors on the sphincter of Oddi, causing smooth-muscle spasm and increased biliary pressure. - This sphincter of Oddi spasm can worsen pain in biliary colic, making morphine the most likely injection given. Nefopam - Nefopam is a centrally acting, non-opioid analgesic that inhibits serotonin, norepinephrine, and dopamine reuptake to provide analgesia. - It is not typically associated with sphincter of Oddi spasm, so it would not be expected to worsen biliary colic in this manner. Ketorolac - Ketorolac is an injectable NSAID that inhibits cyclooxygenase. It can relieve biliary colic and does not characteristically cause morphine-associated sphincter of Oddi spasm. Diclofenac - Diclofenac is an NSAID that reduces prostaglandin synthesis, helping relieve inflammation, pain, and biliary smooth-muscle spasm. - It is commonly useful in biliary colic and does not produce the opioid-related sphincter of Oddi spasm that explains worsening pain.

  3. 3. All of the following help distinguish polyarteritis nodosa from microscopic polyangiitis EXCEPT:

    • A. Red blood cell cast in urine
    • B. ANCA positivity
    • C. HBV infection
    • D. Necrotizing vasculitis
    Show answer

    Answer: D. Necrotizing vasculitis

    Necrotizing vasculitis - Necrotizing vasculitis occurs in both polyarteritis nodosa and microscopic polyangiitis, so it is not a distinguishing feature between them. - The shared finding represents inflammation and necrosis of vessel walls in both disorders, making this the exception. HBV infection - Hepatitis B virus (HBV) infection is associated with a significant subset of polyarteritis nodosa (PAN) cases, but is uncommon in microscopic polyangiitis (MPA). - Therefore, HBV serology can help distinguish these diseases, with a positive result favoring PAN rather than MPA. ANCA positivity - ANCA positivity, especially p-ANCA/MPO-ANCA, occurs frequently in microscopic polyangiitis but is usually absent in polyarteritis nodosa. - This difference reflects MPA's classification as an ANCA-associated vasculitis, unlike PAN, so ANCA status is a useful discriminator. Red blood cell cast in urine - Red blood cell casts indicate glomerulonephritis, a characteristic renal manifestation of microscopic polyangiitis rather than typical polyarteritis nodosa. - This finding reflects glomerular small-vessel injury in MPA; PAN generally spares glomeruli and therefore does not usually produce RBC casts.

  4. 4. A 35-year-old man with new-onset arthritis has sausage digits, nail pitting and scaly plaques over the elbows. What is the most likely diagnosis?

    • A. Juvenile idiopathic arthritis
    • B. Psoriatic arthritis
    • C. Enteropathic arthritis
    • D. Rheumatoid arthritis
    Show answer

    Answer: B. Psoriatic arthritis

    Psoriatic arthritis is supported by the combination of dactylitis, nail pitting and extensor scaly plaques. Juvenile idiopathic arthritis requires onset before 16 years and does not fit this new-onset adult presentation. Enteropathic arthritis can cause dactylitis, but the supplied skin and nail findings favour psoriatic arthritis rather than an inflammatory bowel disease-associated arthropathy. Rheumatoid arthritis typically causes joint-centred swelling and does not explain this characteristic skin–nail–dactylitis combination.

  5. 5. For conventional Point A-based definitive radiotherapy of cervical cancer, what approximate cumulative dose from external-beam radiotherapy plus brachytherapy is delivered to Point A, expressed as EQD2 using an α/β of 10 Gy?

    • A. 8000 rad
    • B. 4000 rad
    • C. 6000 rad
    • D. 10000 rad
    Show answer

    Answer: A. 8000 rad

    8000 rad corresponds to 80 Gy and is the closest listed value to a conventional cumulative Point A target of approximately 80–90 Gy EQD2 from external-beam radiotherapy plus brachytherapy. 10000 rad corresponds to 100 Gy and exceeds this usual cumulative target, although toxicity also depends on organ-at-risk doses and fractionation. 4000 rad corresponds to 40 Gy and is below the usual cumulative definitive target. 6000 rad corresponds to 60 Gy and is also below that target; none of these figures should be interpreted as a universal physical brachytherapy-only dose.

  6. 6. Which of the following statements about drug administration is NOT correct?

    • A. Lipid-soluble drugs for transdermal delivery
    • B. Avoidance of first-pass metabolism parenterally
    • C. Sublingual administration of nitrates for angina relief
    • D. Systemic classification of regional intra-arterial use
    Show answer

    Answer: D. Systemic classification of regional intra-arterial use

    Systemic classification of regional intra-arterial use - This statement is incorrect because regional intra-arterial administration is classified as a local route for delivery to a selected organ or limb. - Although the drug may subsequently enter systemic circulation, this does not change the classification of its intended regional delivery as local. Avoidance of first-pass metabolism parenterally - Parenteral administration generally bypasses the gastrointestinal tract and portal circulation, thereby avoiding significant hepatic first-pass metabolism. - This statement is correct because routes such as intravenous, intramuscular, and subcutaneous administration deliver drugs directly into systemic circulation or tissues rather than through the gut-liver pathway. Sublingual administration of nitrates for angina relief - Sublingual nitrates are absorbed rapidly through the oral mucosa, producing a relatively quick therapeutic effect. - This route avoids extensive hepatic first-pass metabolism, which is important for drugs such as nitroglycerin when swallowed. Lipid-soluble drugs for transdermal delivery - Effective transdermal absorption generally requires substantial lipid solubility so the drug can cross the skin’s lipid-rich stratum corneum. - Suitable transdermal drugs also tend to have low molecular weight and adequate potency; therefore, the statement is considered correct in this context.

  7. 7. What should be the correct treatment for a 14-year-old child with newly diagnosed Juvenile Rheumatoid Arthritis?

    • A. DMARDs with a short course of steroids
    • B. Only NSAIDs
    • C. DMARDs after initial treatment with NSAIDs
    • D. Monotherapy with TNF inhibitors
    • E. Long-term high-dose corticosteroid therapy
    Show answer

    Answer: A. DMARDs with a short course of steroids

    DMARDs with a short course of steroids - DMARDs control disease activity and help prevent progressive inflammation, joint damage, and functional impairment in newly diagnosed juvenile rheumatoid arthritis. - A short corticosteroid course provides rapid anti-inflammatory bridging treatment while DMARDs take effect, minimizing harmful long-term steroid exposure. Only NSAIDs - NSAIDs provide symptomatic relief from pain and inflammation but do not modify the underlying disease or prevent joint damage. - Using NSAIDs alone may allow progressive joint erosion and functional impairment; disease-modifying treatment is required early. DMARDs after initial treatment with NSAIDs - Delaying DMARD initiation until after NSAID treatment allows ongoing inflammation and increases the risk of joint damage. - NSAIDs may provide temporary symptom control, but they should not postpone early disease-modifying therapy when arthritis is newly diagnosed. Long-term high-dose corticosteroid therapy - Long-term high-dose corticosteroids can cause growth suppression, osteoporosis, infection risk, and cushingoid features, making them unsuitable for sustained pediatric therapy. - Steroids may be used briefly as bridging therapy, but disease control should transition to DMARDs rather than prolonged corticosteroid exposure. Monotherapy with TNF inhibitors - TNF inhibitors are biologic DMARDs generally reserved for inadequate response or failure of conventional treatment such as methotrexate. - TNF-inhibitor monotherapy is not usually first-line in treatment-naive disease because conventional DMARD therapy is effective and better established initially.

  8. 8. Tophi in chronic gout are usually found at all the following sites EXCEPT:

    • A. Skeletal muscle
    • B. Articular cartilage
    • C. Cutaneous tissue
    • D. Joint capsule
    Show answer

    Answer: A. Skeletal muscle

    Skeletal muscle - Skeletal muscle is an atypical location for primary tophaceous deposits, compared with articular and periarticular tissues. - Although severe chronic gout may rarely involve muscle, it is not a usual region for tophi and is therefore the exception. Articular cartilage - Articular cartilage is an avascular site where monosodium urate crystals can accumulate in chronic gout. - Crystal deposition in cartilage contributes to erosive changes and progressive joint damage, making this a recognized site for tophi. Joint capsule - The joint capsule is a common site for tophi because of its proximity to affected joints and relatively poor blood supply. - Tophi in the capsule contribute to local inflammation and joint destruction, so this region does not represent the exception. Cutaneous tissue - Cutaneous tissue, particularly subcutaneous tissue around the ears, fingers, toes, and elbows, is a common site of tophus formation. - Cutaneous tophi appear as firm, whitish nodules and are characteristic of chronic tophaceous gout.

  9. 9. In which of the following conditions is Stereotactic Radiosurgery primarily indicated?

    • A. Brain AVM
    • B. Medulloblastoma
    • C. Ependymoma
    • D. Glioblastoma multiforme
    Show answer

    Answer: A. Brain AVM

    Brain AVM - Brain arteriovenous malformations are a primary indication for SRS, especially when small to medium-sized or located in eloquent regions where surgery may be difficult. - SRS delivers a highly focused radiation dose that gradually obliterates abnormal vessels and reduces the long-term risk of hemorrhage. Glioblastoma multiforme - Glioblastoma multiforme is primarily managed with maximal surgical resection followed by concurrent chemoradiotherapy, rather than initial solitary SRS. - SRS may have a role in selected recurrent GBM or as a treatment boost, but it is not the primary indication here. Medulloblastoma - Medulloblastoma is usually a cerebellar tumour managed with surgery, risk-adapted chemotherapy, and radiotherapy including craniospinal irradiation when appropriate; focal stereotactic radiosurgery is not its standard primary treatment. Ependymoma - Ependymoma is usually treated first with surgical resection, with radiotherapy considered as adjuvant treatment when indicated. - Radiotherapy is more commonly delivered as conventional fractionated external-beam therapy, making ependymoma a less characteristic primary indication for SRS.

  10. 10. Which disease-modifying antirheumatic drug's active metabolite inhibits the enzyme dihydro-orotate dehydrogenase?

    • A. Leflunomide
    • B. Methotrexate
    • C. Hydroxychloroquine
    • D. Sulfasalazine
    Show answer

    Answer: A. Leflunomide

    Leflunomide - Leflunomide is a DMARD prodrug converted to teriflunomide (A77 1726), its active metabolite. - Teriflunomide inhibits dihydro-orotate dehydrogenase, blocking de novo pyrimidine synthesis and limiting activated T-lymphocyte proliferation in rheumatoid arthritis. Methotrexate - Methotrexate is a DMARD whose low-dose anti-inflammatory action involves folate-dependent pathways and adenosine signaling. - Its action does not involve an active metabolite inhibiting dihydro-orotate dehydrogenase. Hydroxychloroquine - Hydroxychloroquine is a DMARD that modifies lysosomal and endosomal immune signaling, including Toll-like receptor signaling and antigen processing. - Its action does not involve an active metabolite inhibiting dihydro-orotate dehydrogenase. Sulfasalazine - Sulfasalazine is a DMARD cleaved into sulfapyridine and 5-aminosalicylic acid, with an incompletely defined anti-inflammatory mechanism. - Although it can reduce cytokine release, it does not inhibit dihydro-orotate dehydrogenase or directly block de novo pyrimidine synthesis.

Flashcards: Drugs Used in Rheumatoid Arthritis

  1. 1. IL-4 is an inflammatory cytokine.

    Show answer

    anti-

  2. 2. Which drug useful in gout increases the risk of MI and stroke?

    Show answer

    Febuxostat

  3. 3. What are the two first-line drugs for the treatment of chronic gout? 1. _____ 2. _____

    Show answer

    Allopurinol · Febuxostat — Note: Probenecid is a second-line uricosuric agent used for underexcretors. Current guidelines (e.g., ACR 2020) recommend Xanthine Oxidase Inhibitors like Allopurinol as the first-line therapy for all patients.

  4. 4. The key mediators of redness and warmth in inflammation are _____, _____, and _____

    Show answer

    histamine · prostaglandins · bradykinin

  5. 5. Leflunomide is an antimetabolite that reversibly inhibits _____ preventing _____ synthesis

    Show answer

    dihydroorotate dehydrogenase · pyrimidine

  6. 6. Aspirin at  doses acts by inhibiting cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) both

    Show answer

    high

  7. 7. Patients undergoing long-term aspirin therapy should receive annual vaccination to reduce the risk of Reye syndrome

    Show answer

    influenza

  8. 8. Acute adverse effects of aspirin use are _____ and _____.

    Show answer

    gastric ulceration · tinnitus (CN VIII) (ears ringing)

  9. 9. The effect of intermediate dose aspirin _____ mg/day is _____ and _____

    Show answer

    300-2400 · antipyretic · analgesic

  10. 10. Sulfasalazine is an anti-_____ therapy primarily indicated for _____

    Show answer

    inflammatory · Rheumatoid Arthritis

Everything you need for Indian Medical PG prep

Get full Oncourse access with lessons, practice questions, flashcards and AI study tools.

GET STARTED FOR FREE
75% OFFLimited time offer
GET 75% OFF